IGM Biosciences Inc
IGMS1.308USD
-0.002-0.11%
Market hours （ET）Quotes delayed by 15 min
78.89MMarket Cap
LossP/E TTM
More Details of IGM Biosciences Inc Company
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Company Info
Ticker SymbolIGMS
Company nameIGM Biosciences Inc
IPO dateSep 18, 2019
CEODr. Mary Beth Harler, M.D.
Number of employees149
Security typeOrdinary Share
Fiscal year-endSep 18
Address325 E Middlefield Rd
CityMOUNTAIN VIEW
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94043-4003
Phone16509657873
Websitehttps://igmbio.com/
Ticker SymbolIGMS
IPO dateSep 18, 2019
CEODr. Mary Beth Harler, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
91.71K
+0.91%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
64.03K
+2.05%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Director
Director
62.50K
-50.00%
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
7.74K
-65.20%
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
91.71K
+0.91%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
64.03K
+2.05%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Director
Director
62.50K
-50.00%
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
7.74K
-65.20%
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
No Data
By RegionUSD
Name
Revenue
Proportion
United States
499.00K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Haldor Topsoe Holding A/S
28.42%
Baker Bros. Advisors LP
11.20%
Invus Public Equities Advisors, LLC
8.90%
Redmile Group, LLC
8.07%
Glazer Capital, LLC
6.93%
Other
36.49%
Shareholders
Shareholders
Proportion
Haldor Topsoe Holding A/S
28.42%
Baker Bros. Advisors LP
11.20%
Invus Public Equities Advisors, LLC
8.90%
Redmile Group, LLC
8.07%
Glazer Capital, LLC
6.93%
Other
36.49%
Shareholder Types
Shareholders
Proportion
Corporation
34.02%
Hedge Fund
20.56%
Investment Advisor
16.68%
Investment Advisor/Hedge Fund
13.32%
Individual Investor
3.38%
Research Firm
2.41%
Family Office
0.39%
Bank and Trust
0.04%
Pension Fund
0.02%
Other
9.15%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
241
29.03M
83.43%
-8.92M
2025Q1
258
30.98M
89.26%
-9.33M
2024Q4
261
34.20M
100.37%
-4.65M
2024Q3
262
33.88M
99.73%
-5.05M
2024Q2
269
34.16M
101.16%
-4.19M
2024Q1
277
34.60M
103.20%
-3.37M
2023Q4
277
33.51M
100.77%
-4.17M
2023Q3
286
34.23M
103.22%
-3.29M
2023Q2
291
34.31M
107.60%
+1.63M
2023Q1
295
29.58M
100.36%
-4.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Haldor Topsoe Holding A/S
10.40M
29.88%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
4.10M
11.77%
+1.91K
+0.05%
Jun 30, 2025
Invus Public Equities Advisors, LLC
3.26M
9.36%
-74.60K
-2.24%
Mar 31, 2025
Redmile Group, LLC
2.95M
8.48%
+828.00
+0.03%
Jun 30, 2025
Sanofi SA
1.44M
4.13%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
927.57K
2.67%
-25.39K
-2.66%
Mar 31, 2025
The Vanguard Group, Inc.
875.57K
2.52%
-20.78K
-2.32%
Mar 31, 2025
Goldman Sachs & Company, Inc.
775.15K
2.23%
-190.73K
-19.75%
Mar 31, 2025
State Street Global Advisors (US)
493.70K
1.42%
+34.25K
+7.45%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
